GKOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Glaukos Corp is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has a clear bullish technical setup, strong analyst support, and positive institutional buying, while the main bearish concern is insider selling and some regulatory uncertainty around iDose. Given the user is unwilling to wait for an ideal entry, this still looks like an acceptable entry for a long-term position rather than a trader's perfection setup.
GKOS is in a strong uptrend. Price closed at 149.52, above the previous close of 148.34 and near the R2 resistance level of 151.986, which shows momentum is strong. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, confirming trend strength. MACD histogram is 1.597 and rising, which supports continued upside momentum. RSI_6 at 75.185 suggests the stock is extended in the short term, but the broader trend remains bullish rather than weak. Overall, the chart favors continuation, though near-term upside may be somewhat stretched after the recent move.
["Needham raised its target to $150 and kept a Buy rating after becoming more positive on Glaukos following doctor calls about corneal cross-linking.", "Citi raised its target to $162 and kept a Buy rating, citing substantial runway for Epioxa and underappreciated growth potential.", "Goldman Sachs reported strong Q1 results with revenue and guidance above expectations, helped by iDose adoption and early Epioxa traction.", "BTIG said glaucoma and iDose revenue beat estimates and Epioxa is seeing strong early market development and payer coverage.", "Hedge funds are buying aggressively, with buying up 318.02% over the last quarter."]
["Insiders are selling, with selling amount up 126.48% over the last month.", "Recent investor concern centers on the proposed LCD for iDose, especially the requirement for prior SLT treatment.", "No recent news flow in the last week, so there is no fresh event catalyst to extend the move.", "Short-term technicals show the stock is extended, with RSI above 75 and price near resistance."]
No detailed financial snapshot was available because of a data error, so a full latest-quarter breakdown cannot be completed. However, the available analyst commentary indicates the latest quarter was strong, with Goldman Sachs noting revenue and forward guidance both exceeded elevated expectations. The growth narrative is being driven by accelerating iDose adoption and early traction from Epioxa, which suggests the latest quarter season was favorable and growth trends are improving.
Analyst sentiment is strongly positive and improving. Recent target increases from Needham, Citi, Goldman Sachs, Stifel, JPMorgan, and BTIG show rising confidence in the growth story. The most recent notes highlight Epioxa as a key upside driver and iDose as a continuing growth contributor, although some firms remain focused on possible LCD-related pressure. Wall Street's pros view: strong growth runway, expanding product adoption, and upside from Epioxa. Cons view: reimbursement/LCD risk around iDose and the need for execution to fully support the valuation.
